We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$316M
AUM Growth
-$26.1M
Cap. Flow
+$40.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
62.9%
Holding
48
New
11
Increased
11
Reduced
18
Closed
7
Avg Time Held Equity + Options
2.8 quarters
Top 10 Avg Time Held Equity + Options
2.3 quarters
Top 20 Avg Time Held Equity + Options
3.7 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
2.3 quarters
Top 20 Avg Time Held Equity only
3.7 quarters

Top Buys

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$12.2M
2
PCRX icon
Pacira BioSciences
PCRX
+$12M
3
INSP icon
Inspire Medical Systems
INSP
+$10.1M
4
MDT icon
Medtronic
MDT
+$7.53M
5
DXCM icon
DexCom
DXCM
+$7.04M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$8.8M
3
CNC icon
Centene
CNC
+$7.7M
4
UNH icon
UnitedHealth
UNH
+$7.21M
5
MRVI icon
Maravai LifeSciences
MRVI
+$3.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.39%
2 Industrials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PCRX icon
1
Pacira BioSciences
PCRX
$1.45B
$37.1M 11.77%
1,210,377
+332,791
+38% +$12M
2023 Q1
2 quarters
HUM icon
2
Humana
HUM
$50.5B
$31.6M 10.02%
65,000
+9,900
+18% +$4.65M
2022 Q3
4 quarters
LKFT icon
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$25.2M 8%
730,207
+312,707
+75% +$12.2M
2021 Q1
10 quarters
MGTX icon
4
MeiraGTx Holdings
MGTX
$955M
$20M 6.35%
4,078,804
– –
2022 Q1
6 quarters
KURA icon
5
Kura Oncology
KURA
$874M
$17.6M 5.59%
1,932,456
+589,097
+44% +$5.98M
2023 Q2
1 quarter
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.06B
$17M 5.4%
2,408,135
-91,865
-4% -$660K
2022 Q2
5 quarters
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.17B
$15.6M 4.95%
2,579,802
-181,666
-7% -$1.49M
2022 Q3
4 quarters
MDT icon
8
Medtronic
MDT
$119B
$11.8M 3.73%
150,000
+90,000
+150% +$7.53M
2023 Q2
1 quarter
ABCL icon
9
AbCellera Biologics
ABCL
$4.09B
$11.3M 3.57%
2,446,000
-104,000
-4% -$633K
2022 Q3
4 quarters
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$5.17B
$11.2M 3.54%
353,508
-321,492
-48% -$8.8M
2022 Q1
6 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$13.7B
$9M 2.85%
80,000
-90,000
-53% -$9.48M
2023 Q1
2 quarters
NARI icon
12
DELISTED
Inari Medical, Inc. Common Stock
NARI
$8.5M 2.69%
130,000
+11,316
+10% +$712K
2023 Q1
2 quarters
INSP icon
13
Inspire Medical Systems
INSP
$1.99B
$7.94M 2.52%
+40,000
New +$10.1M
2023 Q3
0 quarters
OPCH icon
14
Option Care Health
OPCH
$4.66B
$7.12M 2.26%
220,000
-15,780
-7% -$532K
2022 Q4
3 quarters
QDEL icon
15
QuidelOrtho
QDEL
$967M
$6.21M 1.97%
85,000
-25,468
-23% -$2.03M
2022 Q1
6 quarters
PRTA icon
16
Prothena Corp
PRTA
$429M
$6.09M 1.93%
126,202
+6,202
+5% +$368K
2020 Q3
12 quarters
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$5.93M 1.88%
3,446,274
+1,446,274
+72% +$4.4M
2023 Q2
1 quarter
DXCM icon
18
DexCom
DXCM
$32.1B
$5.82M 1.85%
+62,421
New +$7.04M
2023 Q3
0 quarters
KZR icon
19
DELISTED
Kezar Life Sciences
KZR
$5.68M 1.8%
477,080
+11,888
+3% +$211K
2021 Q1
10 quarters
CNC icon
20
Centene
CNC
$34B
$5.51M 1.75%
80,000
-115,670
-59% -$7.7M
2023 Q1
2 quarters
UHS icon
21
Universal Health Services
UHS
$10.6B
$5.14M 1.63%
+40,890
New +$5.58M
2023 Q3
0 quarters
ADCT icon
22
ADC Therapeutics
ADCT
$217M
$4.85M 1.54%
5,402,041
-181,859
-3% -$242K
2022 Q3
4 quarters
TDOC icon
23
Teladoc Health
TDOC
$1.09B
$4.65M 1.47%
250,000
+173,100
+225% +$4.04M
2023 Q1
2 quarters
MASI icon
24
DELISTED
Masimo
MASI
$3.51M 1.11%
+40,000
New +$4.66M
2023 Q3
0 quarters
LENZ icon
25
LENZ Therapeutics
LENZ
$107M
$3.32M 1.05%
191,118
-51,739
-21% -$900K
2022 Q3
4 quarters
1
2

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2023 Portfolio in Review

As of Q3 2023, Prosight Management held 48 positions worth $316M, down 7.6% from $342M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management deployed $40.1M of net new capital in Q3 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Inspire Medical Systems: 40,000 shares worth $7.94M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $9.48M trimmed.

  • Prosight Management's largest Q3 2023 buy was Inspire Medical Systems: 40,000 shares worth $7.94M.
  • Prosight Management added most to Lakefront Biotherapeutics American Depositary Shares in Q3 2023, an estimated $12.2M increase.
  • Prosight Management's biggest Q3 2023 reduction was Neurocrine Biosciences, cutting an estimated $9.48M.
  • Prosight Management fully exited UnitedHealth in Q3 2023, selling an estimated $7.21M.
  • Prosight Management's ten largest holdings make up 63% of its $316M portfolio in Q3 2023.
  • Prosight Management opened 11 new positions and closed 7 in Q3 2023.
  • Prosight Management's portfolio value fell 7.6% quarter-over-quarter to $316M.

Based on Prosight Management's 13F filing for Q3 2023, filed 14 Nov 2023.